CYP19A1 and breast cancer: It was alsoshown that GPR30 is able to upregulate aromatase expression in tamoxifen-resistant breastcancer cells, which can be linked to the sensitivity to AIs in breast cancer patients withacquired or de novo resistance to tamoxifen (Catalano et al. 2014).